219
Participants
Start Date
October 27, 2020
Primary Completion Date
November 29, 2021
Study Completion Date
November 29, 2021
Enoxaparin
The treatment provided will be enoxaparin sodium 40mg/0.4 mL. All doses will be provided in pre-filled, single-dose syringes for subcutaneous injection.
Harry Gibbs, National Co-ordinating Investigator, The Alfred Hospital, Melbourne
Dr Frank Cools, National Co-ordinating Investigator, AZ Klina, Brasschaat
Prof. Barry Jacobson, National Coordinating Investigator, University of the Witwatersrand, Johannesburg
Collaborators (1)
Thrombosis Research Institute
OTHER
Sanofi
INDUSTRY